Pursuant to Regulation 30 of the SEBI Listing Regulations and based on the recommendation of the Nomination and Remuneration Committee, Emcure Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held today i.e. Tuesday, May 05, 2026, has approved the re-appointment of the following Directors, subject to approval of shareholders: 1. Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of 1 (One) year commencing from August 28, 2026; 2. Satish Mehta (DIN: 00118691) as the Managing Director of the Company, for a further period of 5 (Five) years with effective from April 01, 2027. Dr. Mukund Gurjar and Satish Mehta are not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that they are not related to any Director(s) or Key Managerial Personnel(s) of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed. The meeting of the Board of Directors of the Company commenced at 12.42 pm (IST) and concluded at 2.00 pm (IST).
The above information is a part of company’s filings submitted to BSE.
